BNTC - NASDAQ
Benitec Biopharma Inc.
$10.58
-1.7%Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
At a Glance
Live SnapshotBenitec Biopharma Inc. Management Team
Ms. Megan Joan Boston B.Com., C.A.
Chief Financial Officer & Director
Compensation
$362,579
Ms. Sophie Mukadam
Chief Operating Officer
Dr. Jerel A. Banks M.D., Ph.D.
Executive Chairman & Chief Executive Officer
Compensation
$665,892
Dr. Michael Graham
Head of Discovery & Founding Scientist
Compensation
$124,858
Dr. Claudia Kloth Ph.D.
Senior Vice President of Manufacturing
Benitec Biopharma Inc. Insider Positioning
During the last 12 months, insiders have purchased $11.94M worth of BNTC shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
162.0K
2.08M
0
0.00
+2.1M
+$2.08M
6-9 Months
730.4K
9.86M
0
0.00
+9.9M
+$9.86M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Suvretta Capital Management, Llc
Director, 10 Percent Owner:
$11.94M
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $11.94M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
1 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Unanimous insider buying: Zero selling combined with active buying is rare and typically very bullish. Insiders appear to see significant upside with limited downside risk.
SEC Filings
BNTC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | October 14, 2025 | December 01, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | October 22, 2024 | December 04, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | July 29, 2024 | August 29, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | October 20, 2023 | December 06, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | October 25, 2022 | December 07, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | October 22, 2021 | December 08, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | October 22, 2020 | December 09, 2020 | 2020 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.